Abstract
Biologic glues have gained increasing acceptance in many areas of surgery. Two of the most popular early glues were cyanoacrylate and gelatin-resorcinol-formaldehyde. Early enthusiasm for these products was tempered by the later observation of significant complications including tissue necrosis, vascular thrombosis, anastomotic stenosis, and pseudoaneurysm formation [1, 2]. In addition, FDA approval was unlikely with formaldehyde classified as a carcinogen. To alleviate concerns about local tissue toxicity and malignancy risk, BioGlue (CryoLife, Kennesaw, GA) substitutes glutaraldehyde for formaldehyde as the active chemical agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
